BioCentury | Oct 18, 2019
Finance

Accelmed’s $100M fund targets early stage digital health plays

...The first venture fund has seen M&A activity of late. In early October, med-tech group AngioDynamics Inc....
BioCentury | Jan 19, 2015
Company News

uniQure management update

...Matthew Kapusta as CFO, formerly SVP of corporate development, strategic planning and national accounts at AngioDynamics Inc. WIR...
BioCentury | Dec 16, 2013
Company News

AngioDynamics management update

...manager Transitioned: John Soto to chief commercial officer, a newly created position, from SVP of AngioDynamics'...
BioCentury | Dec 3, 2012
Company News

AngioDynamics management update

AngioDynamics Inc. (NASDAQ:ANGO), Latham, N.Y. Business: Cancer, Cardiovascular Retiring: EVP and CFO Joseph Gersuk, effective Jan. 31, 2013; he will be succeeded by Mark Frost, SVP of administration and CFO of Albany Molecular Research Inc....
BioCentury | Oct 22, 2012
Company News

AngioDynamics, Vortex Medical Inc. deal

...drainage, filtration and reinfusion of blood for up to six hours (see BioCentury, Oct. 15). AngioDynamics Inc....
BioCentury | Oct 15, 2012
Company News

AngioDynamics, biolitec Inc. cardiovascular, cancer news

...District of New York awarded AngioDynamics $23.2 million in damages in a suit against biolitec. AngioDynamics...
...between the companies. The agreement obligated biolitec, which supplies AngioDynamics with marketed products, to defend AngioDynamics...
...AngioDynamics provides minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and cancer. AngioDynamics Inc....
BioCentury | Oct 15, 2012
Company News

AngioDynamics, Vortex Medical deal

...cash, plus cash payments based on net sales of the AngioVac system over 10 years. AngioDynamics...
...of about $8 million per year for the first five years. After the fifth year, AngioDynamics...
...in fiscal 2014. Angiodynamics reported net sales of $221.8 million for the fiscal year 2012. AngioDynamics Inc....
BioCentury | Oct 8, 2012
Company News

AngioDynamics management update

AngioDynamics Inc. (NASDAQ:ANGO), Latham, N.Y. Business: Cancer, Cardiovascular Hired: Louis Mazzarese as SVP and chief regulatory officer; and John Soto as SVP of the peripheral vascular global franchise, formerly SVP of the global hip franchise...
BioCentury | May 30, 2011
Company News

AngioDynamics, BTG sales and marketing update

...in the U.S. beyond the deal's Dec. 31 expiration date. In April 2006, BTG granted AngioDynamics...
...U.S. BTG said it will begin directly distributing LC Bead in the U.S. in 2012. AngioDynamics...
...AngioDynamics reported $159.5 million in net sales, 13% of which is represented by LC Beads. AngioDynamics Inc....
BioCentury | May 9, 2011
Company News

Delcath management update

...Mapes as EVP of global operations, a newly created position, formerly SVP of operations at AngioDynamics Inc. WIR...
Items per page:
1 - 10 of 14
BioCentury | Oct 18, 2019
Finance

Accelmed’s $100M fund targets early stage digital health plays

...The first venture fund has seen M&A activity of late. In early October, med-tech group AngioDynamics Inc....
BioCentury | Jan 19, 2015
Company News

uniQure management update

...Matthew Kapusta as CFO, formerly SVP of corporate development, strategic planning and national accounts at AngioDynamics Inc. WIR...
BioCentury | Dec 16, 2013
Company News

AngioDynamics management update

...manager Transitioned: John Soto to chief commercial officer, a newly created position, from SVP of AngioDynamics'...
BioCentury | Dec 3, 2012
Company News

AngioDynamics management update

AngioDynamics Inc. (NASDAQ:ANGO), Latham, N.Y. Business: Cancer, Cardiovascular Retiring: EVP and CFO Joseph Gersuk, effective Jan. 31, 2013; he will be succeeded by Mark Frost, SVP of administration and CFO of Albany Molecular Research Inc....
BioCentury | Oct 22, 2012
Company News

AngioDynamics, Vortex Medical Inc. deal

...drainage, filtration and reinfusion of blood for up to six hours (see BioCentury, Oct. 15). AngioDynamics Inc....
BioCentury | Oct 15, 2012
Company News

AngioDynamics, biolitec Inc. cardiovascular, cancer news

...District of New York awarded AngioDynamics $23.2 million in damages in a suit against biolitec. AngioDynamics...
...between the companies. The agreement obligated biolitec, which supplies AngioDynamics with marketed products, to defend AngioDynamics...
...AngioDynamics provides minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and cancer. AngioDynamics Inc....
BioCentury | Oct 15, 2012
Company News

AngioDynamics, Vortex Medical deal

...cash, plus cash payments based on net sales of the AngioVac system over 10 years. AngioDynamics...
...of about $8 million per year for the first five years. After the fifth year, AngioDynamics...
...in fiscal 2014. Angiodynamics reported net sales of $221.8 million for the fiscal year 2012. AngioDynamics Inc....
BioCentury | Oct 8, 2012
Company News

AngioDynamics management update

AngioDynamics Inc. (NASDAQ:ANGO), Latham, N.Y. Business: Cancer, Cardiovascular Hired: Louis Mazzarese as SVP and chief regulatory officer; and John Soto as SVP of the peripheral vascular global franchise, formerly SVP of the global hip franchise...
BioCentury | May 30, 2011
Company News

AngioDynamics, BTG sales and marketing update

...in the U.S. beyond the deal's Dec. 31 expiration date. In April 2006, BTG granted AngioDynamics...
...U.S. BTG said it will begin directly distributing LC Bead in the U.S. in 2012. AngioDynamics...
...AngioDynamics reported $159.5 million in net sales, 13% of which is represented by LC Beads. AngioDynamics Inc....
BioCentury | May 9, 2011
Company News

Delcath management update

...Mapes as EVP of global operations, a newly created position, formerly SVP of operations at AngioDynamics Inc. WIR...
Items per page:
1 - 10 of 14